日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical Trial

晚期乳腺癌一线与二线 CDK4/6 抑制剂治疗的总生存期:一项随机临床试验

Wortelboer, Noor; van Ommen-Nijhof, Annemiek; Konings, Inge R; van der Noort, Vincent; van den Pol, Esther; Guerrero Páez, Cristina; Bakker, Sandra D; Hovenga, Sjoerd; Imholz, Alex L T; Kamm, Yvonne J L; van Leeuwen, Lobke; Luykx-de Bakker, Sylvia A; Mandigers, Caroline M P W; van Riel, Johanna M G H; Tol, Jolien; van de Wouw, Agnes J; Wilting, Saskia M; van Leeuwen-Stok, A Elise; Jager, Agnes; Sonke, Gabe S

Stage I non-small cell lung cancer: improving patient selection for minimally invasive lobectomy or stereotactic ablative radiotherapy based on clinical characteristics

I期非小细胞肺癌:基于临床特征改进微创肺叶切除术或立体定向消融放射治疗的患者选择

de Ruiter, Julianne Cynthia; van der Noort, Vincent; van Diessen, Judi Nani Annet; Smit, Egbert Frederik; Damhuis, Ronald Alphons Maria; Hartemink, Koen Johan

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol

奥拉帕尼用于携带同源重组修复基因改变的肿瘤患者:药物再发现方案的结果

Spiekman, Ilse A C; Mehra, Niven; Zeverijn, Laurien J; Geurts, Birgit S; Verkerk, Karlijn; Haj Mohammad, Soemeya F; van der Noort, Vincent; Roepman, Paul; de Leng, Wendy W J; Jansen, Anne M L; van de Luijtgaarden, Addy C M; van Voorthuizen, Theo; Buffart, Tineke E; Gelderblom, Hans; Voest, Emile E; Verheul, Henk M W

Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial

新辅助伊匹木单抗和纳武利尤单抗治疗可切除皮肤鳞状细胞癌:一项随机II期试验

Breukers, Sabine E; Traets, Joleen J H; van Dijk, Stan W; Ostos, Mercedes Machuca; Fraterman, Itske; Crommelin, Robert D; van der Hulst, Hedda; Qiao, Xiaohang; Boere, Thomas; van de Poll-Franse, Lonneke V; Retèl, Valesca; van der Noort, Vincent; Vos, Joris L; Toppenberg, Alexandra G L; van der Heijden, Martijn; Missale, Francesco; Balm, Fons; van den Brekel, Michiel; Dirven, Richard; Karakullukcu, M Baris; Karssemakers, Luc; Klop, W Martin C; Lohuis, Peter J F M; Schreuder, Willem H; Smeele, Ludi E; van der Velden, Lilly-Ann; Plasmeijer, Elsemieke; Smit, Laura A; de Boer, Jan Paul; Navran, Arash; Westerink, Bram; de Koekkoek-Doll, Petra K; Castelijns, Jonas; Wondergem, Maurits; Vogel, Wouter V; Kuijpers, Anke; van Houdt, Winan J; Onderwater, Suzanne; Maas-Bannink, Esther; Cornelissen, Sten; Broeks, Annegien; Tijink, Bernard M; Devriese, Lot A; de Bree, Remco; Blank, Christian U; Schumacher, Ton N; Thommen, Daniela S; Haanen, John B A G; Zuur, Charlotte L

Iodine Seed-Marking Protocol for Response-Guided Axillary Treatment After Systemic Therapy for Node-Positive Breast Cancer

碘种子标记方案用于淋巴结阳性乳腺癌全身治疗后的反应指导腋窝治疗

van Hemert, Annemiek K E; van Loevezijn, Ariane A; Baas, Marie-Sophie P D; Stokkel, Marcel P M; Groen, Emma J; van der Noort, Vincent; Loo, Claudette E; Sonke, Gabe S; Russell, Nicola; van Duijnhoven, Frederieke H; Vrancken Peeters, Marie-Jeanne T F D

Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study

在晚期非小细胞肺癌中,帕博利珠单抗混合给药方案不劣于固定剂量方案:一项真实世界回顾性双中心队列研究

Smeenk, Michiel M; van der Noort, Vincent; Hendrikx, Jeroen M A; Abedian Kalkhoran, Hanieh; Smit, Egbert F; Theelen, Willemijn S M E

Response to: Comment on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study' by Zhu

回应:朱先生发表的题为“在晚期非小细胞肺癌中,帕博利珠单抗混合给药方案不劣于固定剂量方案:一项真实世界回顾性双中心队列研究”的评论

Smeenk, Michiel M; van der Noort, Vincent; Hendrikx, Jeroen J M A; Abedian Kalkhoran, Hanieh; Smit, Egbert F; Theelen, Willemijn S M E

Response to: Correspondence on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer-a real-world, retrospective bicenter cohort study' by Wang

回复:王教授关于“帕博利珠单抗混合给药方案在晚期非小细胞肺癌治疗中不劣于固定剂量方案——一项真实世界回顾性双中心队列研究”的来信

Smeenk, Michiel M; van der Noort, Vincent; Hendrikx, Jeroen J M A; Abedian Kalkhoran, Hanieh; Smit, Egbert F; Theelen, Willemijn S M E

Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer.

表观遗传分析可识别内分泌耐药性标志物,并为转移性去势抵抗性前列腺癌提供治疗选择

Severson Tesa M, Minnee Emma, Zhu Yanyun, Schuurman Karianne, Nguyen Holly M, Brown Lisha G, Hakkola Sini, Menezes Renee, Gregoricchio Sebastian, Kim Yongsoo, Kneppers Jeroen, Linder Simon, Stelloo Suzan, Lieftink Cor, van der Heijden Michiel S, Nykter Matti, van der Noort Vincent, Sanders Joyce, Morris Ben, Jenster Guido, van Leenders Geert Jlh, Pomerantz Mark, Freedman Matthew L, Beijersbergen Roderick L, Urbanucci Alfonso, Wessels Lodewyk, Nelson Peter S, Corey Eva, Prekovic Stefan, Zwart Wilbert, Bergman Andries M

Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non-Small Cell Lung Cancer: The Induction Trial

在不可切除的局部晚期非小细胞肺癌患者中,化疗放疗前使用曲美利单抗联合度伐利尤单抗:诱导试验

Smeenk, Michiel M; van Diessen, Judi N A; Boellaard, Thierry N; Hartemink, Koen J; de Vries, Jeltje F; van der Noort, Vincent; Badrising, Sushil K; Owers, Emilia C; Monkhorst, Kim; van den Heuvel, Michel M; Theelen, Willemijn S M E